Market capitalization | $33.76m |
Enterprise Value | $17.46m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.07 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-25.43m |
Free Cash Flow (TTM) Free Cash Flow | $-19.35m |
Cash position | $20.02m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
1 Analyst has issued a forecast BioVie Inc:
1 Analyst has issued a forecast BioVie Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.23 -0.23 |
15%
15%
|
|
EBITDA | -25 -25 |
46%
46%
|
EBIT (Operating Income) EBIT | -25 -25 |
46%
46%
|
Net Profit | -26 -26 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.
Head office | United States |
CEO | Cuong Do |
Employees | 14 |
Founded | 2013 |
Website | www.bioviepharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.